secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2026-11-10T22:20:38+00:00
Accession:  0001193125-26-455762
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Rallybio sets 1-for-2 reverse stock split effective Nov. 20 ahead of Avenzo merger
--------------------------------------------------------------------------------

- Board approved a one-for-two reverse split on Nov. 8, 2026; effective 12:01 a.m. ET on Nov. 20, 2026, before the anticipated merger close.
- Issued and outstanding shares will fall from about 5.6 million to about 2.8 million; authorized shares and $0.0001 par value remain unchanged.
- After Nasdaq approvals and merger close, Rallybio plans to rename itself Avenzo Therapeutics and trade under ticker "AVZO" with CUSIP 053928 107.
- Merger agreement dated May 31, 2026 with Avenzo Therapeutics and Farmington Merger Sub; stockholders approved a split range of 1-for-2 to 1-for-9 on Nov. 4.
- No fractional shares will be issued; holders will receive cash equal to fair market value based on the closing price on the split's effective date, with Computershare as exchange agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526455762/0001193125-26-455762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526455762/d162317d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer